proteins are overexpressed in many cancers and implicated in tumor growth, so the development of antagonist that disrupts with the binding of IAP to their partner protein is a promising therapeutic strategy. In an effort to increase cellular activity and improve favorable drug-like properties, we newly designed and synthesized monovalent analogues based on imidazopyrazinone structure of 9. Optimization
凋亡
抑制剂 (IAP) 蛋白在许多癌症中过度表达并与肿瘤生长有关,因此开发可破坏 IAP 与其伙伴蛋白结合的拮抗剂是一种很有前景的治疗策略。为了增加细胞活性并改善有利的类药物特性,我们新设计并合成了基于9
咪唑并
吡嗪酮结构的单价类似物。细胞效力的优化导致17的鉴定,这表 明亚微摩尔活性 (GI 50 = 234 nM) 和 Caspase-3 激活(6.3 倍)在
MDA-MB-231 乳腺癌细胞中增加。这些发现清楚地表明了17 作为开发有效抗癌治疗的有前途的单价拮抗剂。